CETINOR (sildenafil), phosphodiesterase type 5 inhibitor
UROLOGY - New medicinal product
Opinions on drugs - Posted on May 10 2017
Reason for request
- CETINOR has marketing authorisation in adult men with erectile dysfunction.
- It is a 1st-line medicine that has no clinical added value compared with other phosphodiesterase type 5 inhibitors (CIALIS, LEVITRA, SPEDRA).
- Reimbursement is recommended only in men whose erectile dysfunction is very likely to be causally related to a serious and defined organic disease.
Clinical Added Value
|no clinical added value||
Évaluation des médicaments